0.8859
price down icon1.77%   -0.016
after-market Handel nachbörslich: .89 0.0041 +0.46%
loading
Schlusskurs vom Vortag:
$0.9019
Offen:
$0.8905
24-Stunden-Volumen:
69,734
Relative Volume:
0.40
Marktkapitalisierung:
$38.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.4977
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
-0.03%
1M Leistung:
-1.67%
6M Leistung:
-15.63%
1J Leistung:
-77.11%
1-Tages-Spanne:
Value
$0.8656
$0.9077
1-Wochen-Bereich:
Value
$0.7705
$0.92
52-Wochen-Spanne:
Value
$0.6101
$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name
Firmenname
Prelude Therapeutics Inc
Name
Telefon
(302) 467-1280
Name
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Name
Mitarbeiter
131
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
PRLD's Discussions on Twitter

Vergleichen Sie PRLD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PRLD
Prelude Therapeutics Inc
0.8859 50.04M 0 -131.52M -107.56M -1.78
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-19 Hochstufung H.C. Wainwright Neutral → Buy
2024-06-20 Herabstufung Barclays Equal Weight → Underweight
2024-03-13 Eingeleitet JMP Securities Mkt Outperform
2024-02-20 Herabstufung H.C. Wainwright Buy → Neutral
2023-12-19 Herabstufung Morgan Stanley Equal-Weight → Underweight
2022-11-21 Herabstufung BofA Securities Neutral → Underperform
2022-09-09 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-07-29 Eingeleitet Jefferies Buy
2022-03-15 Herabstufung BofA Securities Buy → Neutral
2022-02-28 Herabstufung Barclays Overweight → Equal Weight
2021-10-08 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-07-27 Hochstufung BofA Securities Neutral → Buy
2021-04-26 Eingeleitet H.C. Wainwright Buy
2021-03-09 Eingeleitet Barclays Overweight
2020-11-20 Herabstufung BofA Securities Buy → Neutral
2020-10-20 Eingeleitet BofA Securities Buy
2020-10-20 Eingeleitet Goldman Neutral
2020-10-20 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten

pulisher
May 28, 2025

Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 28, 2025
pulisher
May 26, 2025

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges By Investing.com - Investing.com South Africa

May 26, 2025
pulisher
May 26, 2025

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com

May 26, 2025
pulisher
May 22, 2025

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal - insights.citeline.com

May 22, 2025
pulisher
May 15, 2025

AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE

May 15, 2025
pulisher
May 11, 2025

Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MyChesCo

May 11, 2025
pulisher
May 11, 2025

Mineralys Therapeutics to Present at Bank of America Health Care Conference - MyChesCo

May 11, 2025
pulisher
May 10, 2025

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs - MyChesCo

May 10, 2025
pulisher
May 10, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter

May 10, 2025
pulisher
May 10, 2025

What is HC Wainwright’s Estimate for PRLD Q2 Earnings? - Defense World

May 10, 2025
pulisher
May 09, 2025

SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025 - MyChesCo

May 09, 2025
pulisher
May 09, 2025

Q1 Earnings Forecast for PRLD Issued By HC Wainwright - Defense World

May 09, 2025
pulisher
May 08, 2025

Prelude Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

JPMorgan Chase & Co. Purchases 55,183 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

May 07, 2025
pulisher
May 06, 2025

Prelude Therapeutics (NASDAQ:PRLD) Given Buy Rating at HC Wainwright - Defense World

May 06, 2025
pulisher
May 06, 2025

Prelude Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 06, 2025
pulisher
May 06, 2025

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 06, 2025
pulisher
May 05, 2025

Prelude Therapeutics (PRLD) Rating Reiterated with $5 Target by HC Wainwright | PRLD Stock News - GuruFocus

May 05, 2025
pulisher
May 04, 2025

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025 - MyChesCo

May 04, 2025
pulisher
May 04, 2025

Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - Defense World

May 04, 2025
pulisher
May 04, 2025

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MyChesCo

May 04, 2025
pulisher
May 02, 2025

Prelude Therapeutics Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 02, 2025

Renaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

May 02, 2025
pulisher
May 01, 2025

Prelude Therapeutics to Participate in Citizens Life Sciences Conference - Bluefield Daily Telegraph

May 01, 2025
pulisher
May 01, 2025

Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo

May 01, 2025
pulisher
May 01, 2025

JMP Securities Reaffirms Market Outperform Rating for Prelude Therapeutics (NASDAQ:PRLD) - Defense World

May 01, 2025
pulisher
Apr 29, 2025

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies - MSN

Apr 29, 2025
pulisher
Apr 29, 2025

JMP maintains $4 target on Prelude Therapeutics stock By Investing.com - Investing.com Canada

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MyChesCo

Apr 29, 2025
pulisher
Apr 25, 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting | PR - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Prelude Therapeutics Presents Preclinical Data on First-in-Class SMARCA2 and Selective KAT6A Degraders at AACR Annual Meeting - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting - Yahoo Finance

Apr 25, 2025
pulisher
Apr 23, 2025

Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MyChesCo

Apr 23, 2025
pulisher
Apr 17, 2025

Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo

Apr 17, 2025
pulisher
Apr 11, 2025

HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN

Apr 10, 2025
pulisher
Apr 07, 2025

PRLD stock touches 52-week low at $0.61 amid market challenges - Investing.com

Apr 07, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo

Apr 02, 2025
pulisher
Apr 01, 2025

Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 29, 2025

Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo

Mar 29, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics stock surges on insider buying - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

PRLD stock touches 52-week low at $0.66 amid sharp annual decline - Investing.com

Mar 26, 2025

Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):